Anti-virus agent 2

Anti-virus agent 2 (compound 8l) potently inhibits VTT-Fluc replication in Vero cells with an EC₅₀ of 6.1 μM and a selective index of 64.7, and moderately inhibits MPXV clade IIb replication in Vero cells with an EC₅₀ of 47.1 μM^[1].
Anti-virus agent 2 (5-25 μM; 1 h at specified time points, followed by 23 h culture) interferes with viral membrane fusion and intracellular biosynthesis stages of VTT-Fluc replication in Vero cells when administered 1 hour postinfection^[1].
Anti-virus agent 2 (60 s association, 60 s dissociation) binds specifically to viral cap-specific mRNA methyltransferase with a K_D of 7.64 μM^[1].
Anti-virus agent 2 (40 μM; 2 h, then heated at 37-73 °C for 4 min) enhances the thermal stability of viral cap-specific mRNA methyltransferase, confirming a high-affinity interaction^[1].
Anti-virus agent 2 binds specifically to viral A17L protein with a K_D of 7.28 μM, and binds weakly to human cap methyltransferase 2 with a K_D of 491 μM, demonstrating selectivity for viral MTase over the human homolog^[1].
Anti-virus agent 2 (6.25-100 μM; 24 h) has low cytotoxicity in human A549, H460, and CX-1 cell lines, with CC₅₀ values greater than 100 μM^[1].
Anti-virus agent 2 forms a covalent Michael addition adduct with L-serine, and covalently modifies Ser155 of viral cap-specific mRNA methyltransferase and Ser140 of viral A17L protein via Michael addition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.